Poly polymerase inhibitors

Bryant HE and Helleday T (2004) Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents. Biochem Soc Trans 32 959-961... 

Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR (2000) Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6 2860-2867... 

Kaye SB, Lubinski J, Matulonis U et al (2012) Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCAI or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30 372-379... 

Meier, H.L. (1996). The time-dependent effect of 2,2 -dichlor-odiethyl sulfide (sulfur mustard, HD, l,l -thiobis [2-chloro-ethane]) on the lymphocyte viability and the kinetics of protection by poly(ADP-ribose) polymerase inhibitors. Cell. Biol. Toxicol. 12 147-53. 

Meier, H.L., Millard, C., Moser, J. (2000). Poly(ADP-ribose) polymerase inhibitors regulate the mechanism of sulfur mustard-initiated cell death in human lymphocytes. J. Appl. Toxicol 20 S93-100. 

Thomas HD, et al. Preclinical selection of a novel poly(ADP- 159. ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 2007 6 945-956. 

Clark RS, et al. Local administration of the poly(ADP-ribose) 160. polymerase inhibitor INO-1001 prevents NAD- -depletion and improves water maze performance after traumatic brain injury 161. in mice. J. Neurotrauma 2007 24 1399-1405. 

Sims, J.L., Berger, S.J. and Beigcr, N.A. (1983). Poly-ADP-ribose polymerase inhibitors preserve NAD and ATP levels in DNA-damaged cells mechanism of stimulation of unscheduled DNA synthesis. Biochemistry 22, 5188-5194. 

Ray SD, et al. (1992) Ca-activated DNA fragmentation and dimethylnitrosamine-induced hepatic necrosis Effects of Ca -endonuclease and poly(ADP-ribose) polymerase inhibitors in mice. Journal of Pharmacology and Experimental Therapeutics 263(1) 387-394. 

Komjati K, Besson VC, Szabo C (2005) Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma. Curr Drug Targets CNS Neurol Disord 4 179-194... 

Czapski GA, Cakala M, Kopczuk D et al. Effect of poly(ADP-ribose) polymerase inhibitors on oxidative stress evoked hydroxyl radical level and macromolecules oxidation in cell free system of rat brain cortex. Neurosci Lett 2004 356(l) 45-48. 

Virag L, Szabo C. The therapeutic potential of poly(ADP-Ribose) polymerase inhibitors. Pharmacol Rev 2002 54(3) 375-429. 

Cosi C, Colpaert F, Koek W et al. Poly(ADP-ribose) polymerase inhibitors protect against MPTP-induced depletions of striatal dopamine and cortical noradrenaline in C57B1/6 mice. Brain Res 1996b 729(2) 264-9. 

Suh SW, Aoyama K, Chen Y et al. Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J Neurosci 2003 23(33) 10681-90. 

Coppola S, Nosseri C, Maresca V et al. Different basal NAD levels determine opposite effects of poly(ADP-ribosyl)polymerase inhibitors on H202-induced apoptosis. Exp Cell Res 1995 221(2) 462-469. 

Palomba L, Sestili P, Columbaro M et al. Apoptosis and necrosis following exposure of U937 cells to increasing concentrations of hydrogen peroxide The effect of the poly(ADP-ribose)polymerase inhibitor 3-aminobenzamide. Biochem Pharmacol 1999 58(11) 1743-1750. 

Tentori L, Balduzzi A, Portarena I et al. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ 2001 8(8) 817-828. 

Moroni F, Meli E, Peruginelli F et al. Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 2001 8(9) 921-932. 

Chatterjee PK, Thiemermann C. Poly(ADP-ribose) polymerase inhibitors and acute renal failure. In Zhang J, ed. Therapeutic Utilities of PARP Inhibitors. Boca Raton CRC Press, 2002 149-168. 

Raez 1, Tory K, Galiyas Jr F et al. BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor -protects against nephrotoxicity of cisplatin without compromisii its antitumor activity. Biochem Pharmacol 2002 63 1099-1111. 

Bozlu M, Eskandari G, Cayan S et al. The effect of poly (adenosine diphosphate-ribose) polymerase inhibitors on biochemical changes in testicular ischemia-reperfusion injury. J Urol 2003 169 1870-1873. 

Mazzon E, Sertaino I, Li JH et al. GPI 6150, a poly (ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in tat models of inflammation. Eur J Pharmacol 2001 415 85-94. 

Ehrlich W, Huser H, Kroger H. Inhibition of the induction of collagenase by interleukin-1 P in cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide. Rheumatol Int 1995 15 171-2. 

Nalc awa K, Utsunomiya J, Ishikawa T. Inhibition of methylazoxymethanol acetate initiation of colon carcinogenesis in rats by treatment with the poly(ADP-ribose)polymerase inhibitor 3-aminobenzamide. Carcinogenesis 1988 9(7) 1167-1171. 

Bowman KJ, White A, Golding BT et al. Potentiation of anticancer agent cytotoxiciry by the potent poly(ADP-ribose) polymerase inhibitors, NU1025 and NU1064. Br J Cancer 1998 78 1269-1277. 

Bernges F, Zeller WJ. Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA damaging agents in ovarian tumor cell lines - with special reference to cisplatin. J Cancer Res Clin Oncol 1996 122 665-670. 

Boulton S, Pemberton LC, Porteous JK et al. Potentiation of temozolomide cytotoxicity A comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995 72 849-856. 

Miknyoczki SJ, Jones-Bolin S, Prichard S. Chemopotentiation of temozlomide, irinotecan and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. 2003 2 371-382. 

Tentori L, Turriziani M, Franco D et al. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukaemic cells resistant to triazine compounds. Leukemia 1999 13 901-909. 

Tentori L, Leonetti C, Scarsella M et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing haematolo cal malignancy at the central nervous system site. Blood 2002 99 2241-4. 

Zhu, G.D., Rosenberg, S.H., Giranda, V.L., and Frost, DJ. (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res., 13 (9), 2728-2737. 

Sims JL, Sikorski GW, Datino DM, Berger S, Berger NA (1982) Poly (adenosine diphospho-ribose) polymerase inhibitors stimulate unscheduled deoxyribonucleic acid synthesis in normal human lymphocytes. Biochemistry 21 1813-1821... 

---